Mechanisms of resistance to vitamin D action in human cancer cells by Larriba, María Jesús & Muñoz Terol, Alberto
 1 




and Alberto Muñoz 
Instituto de Investigaciones Biomédicas "Alberto Sols", Consejo Superior de Investigaciones 
Científicas-Universidad Autónoma de Madrid, Arturo Duperier 4, E-28029 Madrid, Spain. 
Corresponding autor: Alberto Muñoz. E-mail: amunoz@iib.uam.es 
 
Abstract 
Initial clinical trials in cancer patients with vitamin D compounds have shown acceptable 
toxicity but low activity. A number of mechanisms responsible for resistance to their action in 
cancer cells have been recently reported. They include reduced intracellular availability of 
1 ,25-dihydroxyvitamin D3 (1,25(OH)2D3), loss of vitamin D receptor (VDR) expression and 
deregulation of transcription corepressors that modulate VDR action. Here, we summarize the 
data in the literature on the altered activity of the enzymes (CYP27B1, CYP24A1) that 
controls 1,25(OH)2D3 levels, the repression of VDR by the transcription factor Snail1 and the 
overexpression of several VDR corepressors (NCoR, SMRT) in cancer cells. A better 
understanding of these processes must contribute to improved protocols for the clinical use of 
vitamin D compounds. 
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The classical consideration of vitamin D as a regulator of calcium and phosphate metabolism 
and bone biology began to change in 1981, when David Feldman’s and Tatsuo Suda’s groups 
showed that the most active vitamin D metabolite 1 ,25-dihydroxyvitamin D3 (1,25(OH)2D3, 
calcitriol) inhibited the proliferation of melanoma cells and induced the differentiation of 
leukemic cells [1, 2]. These seminal, pioneer findings opened a new era in the study of 
1,25(OH)2D3, which is now seen as a hormone with pleiotropic effects in the organism. 
A large number of epidemiological and experimental studies performed in cultured cells and 
animal models over the last thee decades support a cancer preventive and, perhaps, a 
therapeutic role for 1,25(OH)2D3 and a series of synthetic vitamin D analogs [3, 4, reviews]. 
The initial phase I and phase II cancer clinical studies showed acceptable toxicity but low 
activity of these compounds [5, review]. As is usual in the development of new antitumoral 
drugs, patients enrolled in these trials were not responding to any other therapy, and they 
were unselected in terms of putative responsiveness to vitamin D compounds. Recent data on 
the physiology of the vitamin D system improve our understanding of the action of 
1,25(OH)2D3 at the molecular and cellular level, which may in turn help us to design future 
clinical trials more rationally. In this chapter, we summarize current knowledge on the 
mechanisms that dictate the response or resistance to 1,25(OH)2D3 in human cancer cells. The 
mechanisms have been grouped into three classes: a) the bioavailability of 1,25(OH)2D3 in 
the cell, b) the integrity and level of expression of the vitamin D receptor (VDR); and c) the 
pattern of expression of the transcription coregulators (coactivators and corepressors) that 
modulate VDR action. 
1,25(OH)2D3 action in human cancer cells. The anticancer action of 1,25(OH)2D3 relies on 
several mechanisms at the cell level: inhibition of proliferation, invasion and angiogenesis, 
sensitization to apoptotic stimuli, induction of differentiation, and modulation of the immune 
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system [3-5]. In each type of cancer, the combined effect of these mechanisms on tumor and 
stromal cells may determine 1,25(OH)2D3 action. 
1,25(OH)2D3 has two types of effect on target cells: the regulation of transcription rate of a 
large number of genes (genomic effects), and the rapid, transcription-independent modulation 
of the activity of membrane ion channels and cytosolic kinases, phosphatases and 
phospholipases (non-genomic effects). Most studies indicate that both types of effect are 
mediated by 1,25(OH)2D3 binding to, and activation of VDR. This is a member of the 
superfamily of nuclear receptors that is expressed in many cell types, and it acts as a ligand-
modulated transcription factor regulating gene expression. A few studies have proposed the 
existence of 1,25(OH)2D3 receptors other than VDR, but their confirmation as physiological 
mediators of 1,25(OH)2D3 action is pending [3, 5]. 
The current model for gene activation by 1,25(OH)2D3-VDR predicts that unliganded VDR 
bound (forming a heterodimer with RXR, the retinoid X receptor) to regulatory sequences 
(vitamin D response elements or VDRE) in target genes represses their transcription by 
recruiting corepressors (NCoR, SMRT…) and histone deacetylases. 1,25(OH)2D3 induces a 
conformational change in VDR that results in the replacement of corepressors by coactivators 
(SRC1, NCoA2…) and increased histone acetylase activity. This results in the opening of 
chromatin structure thus allowing entry of the basal RNA polymerase II transcription 
machinery (Fig. 1) [6, review]. The mechanism of gene repression by 1,25(OH)2D3 is less 
known, although this process is probably equally important for its action, as around one third 
of the target genes are inhibited. In addition to the direct blockade of RNA polymerase II 
activity by binding to VDREs located close to the transcription initiation site, gene repression 
may be due to competition for DNA binding with other transcription factors or to interference 
of their transcription regulatory function (by protein-protein interaction or modulation of their 
phosphorylation) [5]. 
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These considerations indicate that 1,25(OH)2D3 acts by modulating VDR action, and that 
such action is fine-tuned by its interaction with coregulators (coactivators and corepressors). 
1,25(OH)2D3 is the most active vitamin D metabolite because it has the highest affinity for 
VDR binding. 1,25(OH)2D3 is synthesized from 25-hydroxyvitamin D3 (25(OH)D3) by the 
action of the 25-hydroxyvitamin D3 1 -hydroxylase (CYP27B1). As discussed below, this 
has long been thought to take place only in the kidney, but it is now known to occur in 
several other cell types including colon, breast, and prostate normal and transformed 
epithelial cells. Intracellularly, 1,25(OH)2D3 is degraded by further hydroxylation at position 
24 by the ubiquitous enzyme 24-hydroxylase (CYP24A1) [3, 5]. 
In summary (Fig. 1), cell responsiveness to 1,25(OH)2D3 primarily relies on the expression of 
VDR. Second, VDR activity depends on cellular 1,25(OH)2D3 levels that result from the 
balance between the circulating concentrations of 25(OH)D3 and 1,25(OH)2D3, that cross the 
plasma membrane by either passive or facilitated (carrier-mediated) diffusion, and the 
cellular activity of CYP27B1 and CYP24A1 enzymes that control 25(OH)D3 conversion into 
1,25(OH)2D3 and subsequent degradation of this molecule. Third, the pattern of expression of 
coactivators and corepressors modulates VDR activity, thus establishing the precise mode 
and strength of the effects of 1,25(OH)2D3 on the transcription of target genes. An additional 
overimposed level of regulation comes from other signals that may trigger molecular 
pathways affecting the post-translational (phosphorylation) modification, intracellular 
location, or half-life (polyubiquitylation) of VDR or any of its coregulators. 
Resistance due to reduced bioavailability of 1,25(OH)2D3 within cancer cells. Ligand 
occupancy and activation of VDR depends on the levels of circulating 25(OH)D3 (nM range) 
and 1,25(OH)2D3 (pM range) that enter the cell from the bloodstream and on the cellular 
activity of CYP27B1 and CYP24A1 enzymes that regulate respectively the conversion of 
25(OH)D3 into 1,25(OH)2D3 and the degradation of this molecule. Obviously, vitamin D 
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deficiency due to insufficient vitamin D3 synthesis or diet contribution will determine low 
circulating 25(OH)2D3 levels. Decreased renal CYP27B1 expression or activity has the same 
consequence. Kidney CYP27B1 was long time considered the only source of 1,25(OH)2D3, 
which would then reach the bloodstream and act on target tissues in an endocrine fashion. 
The finding, however, of CYP27B1 expression and activity in normal and tumoral colon 
epithelial cells and later in other cell types (prostate, breast) demonstrated that 1,25(OH)2D3 
has paracrine and autocrine activity that may be involved in a defense mechanism against 
cancer progression [7, 8]. 1,25(OH)2D3 rapidly and strongly induces CYP24A1 expression, 
leading to an increase in the metabolism of 1,25(OH)2D3 [8]. 
Interestingly, a number of studies have reported differences in CYP27B1 and/or CYP24A1 
expression/activity between normal and tumoral cells. This has led to the currently accepted 
idea that, in cancer cells, attenuated CYP27B1 expression or activity or accelerated 
1,25(OH)2D3 elimination by CYP24A1 overexpression leads to reduced VDR activation and 
1,25(OH)2D3 resistance. Colon, prostate and breast cancer cells in culture show reduced 
CYP27B1 expression, which in some cases appears to be a consequence of epigenetic 
alteration of the genetic locus, as treatment of cells with methylation or deacetylation 
inhibitors increased CYP27B1 expression [9]. One study has proposed that the mechanism of 
decreased CYP27B1 activity in prostate cancer cell lines is via decreased gene expression 
while in primary cultures and tissues it is post-translational [10]. Moreover, the finding that 
CYP27B1 is also present in tumor infiltrating macrophages suggests an immunomodulatory 
component of 1,25(OH)2D3 production in some types of cancer [8]. 
CYP24A1 overexpression is commonly held responsible for the partial or total resistance of 
colon, breast and prostate cancer cells to 1,25(OH)2D3 effects. In line with this, combination 
of 1,25(OH)2D3 with inhibitors of vitamin D3 metabolizing enzymes or antisense inhibition of 
CYP24A1 caused a greater inhibition of proliferation of human prostate and breast cancer 
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cells than 1,25(OH)2D3 alone [11, 12]. In colon cancer cells, 1,25(OH)2D3 downregulates 
CYP27B1 and induces CYP24A1 in such a way that CYP27B1 is active only if CYP24A1 is 
not maximally functional, and that the malignancy of tumor cells determines the extent of 
1,25(OH)2D3 catabolism [13]. Additionally, CYP24A1 polymorphisms or splicing variants 
(modulated by 1,25(OH)2D3) may render different levels of constitutive and inducible 
CYP24A1 activity at least in prostate cancer cell lines [14]. The relevance of CYP24A1 
regulation has recently been extended by the finding that epigenetic silencing of CYP24A1 
contributes to the selective growth inhibition that 1,25(OH)2D3 induces in tumor-derived 
endothelial cells as compared to endothelial cells of non-tumor origin [15]. 
Taken together, these data indicate that enzymes involved in vitamin D metabolism may be 
important targets for cancer prevention and treatment. This is supported by in vitro studies 
that use epigenetic inhibitors or vitamin D analogs that prevent the increase of CYP24A1 
activity [16]. Furthermore, antineoplastic agents of clinical use such as daunorubicin 
hydrochloride, etoposide and vincristine sulphate increase the intracellular level of 
1,25(OH)2D3 by decreasing the stability of CYP24A1 mRNA [17]. This action would prolong 
the bioavailability of 1,25(OH)2D3 and may thus form the basis for putative additive or 
synergistic anticancer treatments. Importantly, during the aging the activity of CYP27B1 
decreases while that of CYP24A1 increases, which contributes to partial resistance to vitamin 
D in the elderly. 
Resistance to 1,25(OH)2D3 due to VDR repression. Cellular response to 1,25(OH)2D3 mainly 
depends on VDR expression levels. VDR is expressed in almost all cell types and tissues. 
Epithelial cells from gastrointestinal tract, breast, kidney, prostate, bladder and liver contain 
VDR. Moreover, VDR is expressed in bone, muscle and skin cells as well as some activated 
cells of the immune system [3]. Tumor cells derived from these tissues usually express VDR 
and maintain the capacity to respond to 1,25(OH)2D3. Remarkably, elevated VDR expression 
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is associated with high differentiation, absence of node involvement and favourable prognosis 
in colorectal cancer [18-20], and with late development of lymph node metastases and longer 
disease-free survival in breast cancer [21, 22]. However, downregulation of VDR expression 
has been found in several tumors (colon, breast, lung…) compared with their corresponding 
normal tissue [7, 23]. In colon cancer, VDR expression is induced in the early stages of 
tumorigenesis (polyps and adenomas) and decreases during colon cancer progression [7]. 
Clinical response to 1,25(OH)2D3 analogs requires the expression of VDR in tumoral cells. 
Therefore, the downregulation of VDR found in tumors will lead to 1,25(OH)2D3 
unresponsiveness and resistance not only to the therapy with 1,25(OH)2D3 analogs but also to 
the antitumoral effects of endogenous 1,25(OH)2D3. 
Deletions, rearrangements or point mutations affecting the coding region of the VDR gene 
have not been found in cancer. Several polymorphisms have been described in the VDR gene, 
some of which have been associated with increased risk of breast, prostate and colon cancer. 
However, their consequences for VDR expression or functionality, and therefore their 
implication in the development of 1,25(OH)2D3 resistance remain to be established [24]. 
A mechanism responsible for VDR downregulation, at least in colon cancer, has emerged in 
the last years. Our group has revealed that the transcription factor Snail1 binds to the human 
VDR gene promoter and represses its expression in human colon cancer cells. In addition, 
Snail1 also reduces VDR mRNA half-life [25]. Accordingly, overexpression of Snail1 in 
human colon cancer cells blocks the prodifferentiation action of 1,25(OH)2D3 and its 
inhibitory effect on cell proliferation and migration. Snail1 also represses VDR expression 
and abrogates the antitumoral effect of EB1089 (a 1,25(OH)2D3 analog) in xenografted mice 
(Fig. 2) [25, 26]. Upregulation of Snail1 has been found in approximately 60% of colon 
tumors and it has been significantly associated with diminished VDR expression [25, 27]. 
These data indicate that Snail1 induction is probably responsible for VDR downregulation 
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during colon cancer progression and indicate that tumors with high Snail1 expression would 
be resistant to treatment with 1,25(OH)2D3 or its analogs. Since Snail1 is up-regulated in 
advanced tumors (associated with acquisition of migratory and invasive properties), 
1,25(OH)2D3 and its analogs should preferentially be used as chemopreventive drugs, 
particularly for high risk patients, and as chemotherapeutic agents to be administered during 
the early stages of carcinogenesis [28]. In addition, as Snail1 up-regulation has been reported 
in cancers other than colon (synovial sarcoma and breast, gastric and hepatocellular 
carcinomas) [29, review] this mechanism could be responsible for VDR downregulation and 
vitamin D resistance in other tumors. It has also been shown that H-ras transformation of 
HC11 mammary cells or NIH 3T3 fibroblasts provokes a reduction of VDR mRNA levels 
leading to 1,25(OH)2D3 resistance. In these cases, transcriptional repression was ruled out and 
VDR downregulation seemed to be due to a decrease in VDR mRNA stability [30, 31]. As the 
Ras-Raf-MAPK pathway is one of the inducers of Snail1 [29], VDR downregulation by 
oncogenic H-ras is probably mediated by Snail1. Remarkably, ectopic VDR re-expression 
diminished H-ras-induced transformation in NIH 3T3 cells [31]. 
Several studies have identified compounds that increase VDR expression and/or 1,25(OH)2D3 
level in cancer and, therefore, could overcome the 1,25(OH)2D3 resistance of tumors. 
1,25(OH)2D3 synthesis and VDR expression can be regulated by estrogens in colon cancer. 
17 -estradiol and certain phytoestrogens induce VDR and CYP27B1 expression while they 
reduce that of CYP24A1. Therefore, the treatment of tumors with estrogens would increase 
VDR levels and overcome the resistance to 1,25(OH)2D3 analogs [32]. In addition, the 
transcription factor p53 and its family members p63 , p73  and p73  activate human VDR 
gene transcription. These transcription factors are activated in turn by genotoxic stresses such 
as certain chemotherapeutic drugs. It is therefore expected that combined treatment with 
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chemotherapy may enhance cell sensitivity to the antitumoral effects of 1,25(OH)2D3 because 
the increase in the levels of p53 family members by chemotherapy could induce VDR [32]. 
Resistance to 1,25(OH)2D3 due to altered expression of VDR coregulators. Interestingly, 
tumoral resistance to 1,25(OH)2D3 appears to be unrelated to VDR levels in several 
situations, because there is no clear relation between VDR expression and 1,25(OH)2D3 
action [24]. Therefore, various groups began to examine whether epigenetic mechanisms 
were disrupting VDR signalling, and they found that these mechanisms caused decreased 
responsiveness to 1,25(OH)2D3 in prostate and breast cancer [33]. This epigenetic corruption 
results from an abnormal pattern of expression of corepressors or coactivators. In addition, 
altered post-translational modifications of VDR or RXR may also diminish VDR 
transcriptional activity. 
Elevated expression of the corepressors SMRT and NCoR has been reported in prostate and 
breast cancer cell lines, respectively [34, 35]. Moreover, an increased ratio of 
corepressor/VDR RNA is also observed in matched primary tumor and normal breast cells, 
particularly associated with estrogen receptor negativity [35]. This alteration causes 
resistance to the antiproliferative effect of 1,25(OH)2D3, which can be restored with inhibitors 
of histone deacetylases (trichostatin) and DNA methyltransferases (5-aza-2’-deoxycytidine) 
[34-36]. This also explains the synergistic inhibitory effect of combined treatment with 
1,25(OH)2D3 and sodium butyrate or trichostatin on the proliferation of prostate cancer cells 
[37]. The abnormal expression of coregulators may explain why VDR content does not 
predict the antiproliferative effects of 1,25(OH)2D3 in some cancer cells [24]. Interestingly, in 
line with the increasing tendency to consider stroma as a critical regulator of tumor 
progression, altered VDR-mediated transcriptional activity due to abnormal VDR DNA 
binding and SMRT recruitment has been described in prostate cancer stroma [38]. 
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In contrast to what happens with corepressors, there is no report of alterations in the 
expression of VDR coactivators. The lack of such alterations in cancer cells may be a 
consequence of a dominant role of corepressor overexpression, which upsets the equilibrium 
between the two types of coregulators in normal cells. Bikle and collaborators hypothesized 
that the reason why squamous cell carcinoma cells fail to respond to the prodifferentiating 
action of 1,25(OH)2D3, in spite of having normal levels of VDR and normal binding of VDR 
to VDREs, is a failure of the sequential binding of coactivator complexes to VDR [39]. 
Finally, although data in the literature are scarce, deregulation of the translational 
modifications of VDR and RXR are believed to affect the gene regulatory activity of 
1,25(OH)2D3. In the transformed human keratinocyte cell line HPK1Aras, RXR  is 
phosphorylated at serine 260, which attenuates the transcriptional activity of VDR-RXR 
heterodimers and results in resistance to the growth inhibitory action of 1,25(OH)2D3 [40]. 
HPK1Aras cells overexpress the H-ras oncogene and consequently exhibit an activated Ras-
Raf-MAPK pathway. As this pathway is usually activated in many human cancer cells due to 
mutation or overexpression of membrane tyrosine kinase receptors (EGFR, MET) or 
downstream components such Ras or Raf, the importance of this type of alteration may be 
greater than suspected. VDR is known to be phosphorylated at several residues, although the 
significance of this remains to be assessed. 
Concluding remarks. 1,25(OH)2D3 is a pleiotropic hormone with a complex variety of actions 
in the organism which are mediated by its high affinity receptor VDR, present in most cell 
types. VDR is expressed by many tumor cells. However, partial-to-total resistance to the 
antitumoral effects of 1,25(OH)2D3 arises during tumor progression. This is due to the 
reduced levels of 1,25(OH)2D3 in cancer cells, loss of VDR expression or deregulation of 
VDR transcriptional activity. The molecular mechanisms responsible for these alterations are, 
respectively, the deregulation of the enzymes synthesizing and degrading 1,25(OH)2D3 
 11 
intracellularly (CYP27B1 and CYP24A1), the upregulation of Snail1 and perhaps other 
transcriptional repressors of VDR, and alterations in the synthesis or post-translational 
modifications of VDR corepressors or partners. Better understanding of these mechanisms of 
resistance may allow us to improve the anticancer therapy with 1,25(OH)2D3 and its analogs. 
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Figure Legends 
Figure 1. Schematic representation of 1,25(OH)2D3 metabolism and action in human cancer 
cells and of the mechanisms of resistance to 1,25(OH)2D3. Cancer epithelial cells receive 
25(OH)D3 and 1,25(OH)2D3 (in the nM and pM range, respectively) from the bloodstream 
and synthesize 1,25(OH)2D3 from 25(OH)D3 by CYP27B1 action. 1,25(OH)2D3 binding to 
VDR induces a conformational change that leads to the replacement of corepressors (SMRT, 
NCoR) by coactivators (SRC1, NCoA2) and finally induces the transcriptional activation of 
many genes involved in different cellular functions related to 1,25(OH)2D3 antitumoral 
action. Alteration of the expression and activity of the enzymes regulating 1,25(OH)2D3 
synthesis (CYP27B1) and catabolism (CYP24A1) have been found in cancer, and they cause 
the reduction of intracellular 1,25(OH)2D3 levels. Similarly, VDR repression and aberrant 
expression of transcriptional coactivators or corepressors have been found in cancer and they 
lead to 1,25(OH)2D3 resistance. 
Figure 2. Immunohistochemistry analysis of the expression of VDR and Snail1 in 
xenografted tumors generated in immunodeficient mice by human SW480-ADH colon cancer 
cells that were infected with retroviruses coding for the hemmaglutinin (HA)-tagged mouse 
Snail1 cDNA or an empty virus (Mock). As shown by the use of anti-VDR and anti-HA 
antibodies, Snail1 overexpression downregulates VDR levels. 
